The Unique Characteristics of Tumor Vasculature and Preclinical Evidence for Its Selective Disruption by Tumor-Vascular Disrupting Agents

Overview

Journal Cancer Treat Rev

Publisher Elsevier

Specialty Oncology

Date 2010 Jun 24

PMID 20570444

Citations 249

Authors

Dietmar W Siemann

Affiliations

Soon will be listed here.

Abstract

The vasculature of solid tumors is fundamentally different from that of normal vasculature and offers a unique target for anti-cancer therapy. Direct vascular-targeting with Tumor-Vascular Disrupting Agents (Tumor-VDAs) is distinctly different from anti-angiogenic strategies, and offers a complementary approach to standard therapies. Tumor-VDAs therefore have significant potential when combined with chemotherapy, radiotherapy, and angiogenesis-inhibiting agents. Preclinical studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects.

Citing Articles

Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice.

Wanniarachchi H, Schuetze R, Deng Y, Hamal K, Pavlich C, Tankoano P Cancers (Basel). 2025; 17(5).

PMID: 40075618 PMC: 11898701. DOI: 10.3390/cancers17050771.

Platelet hitchhiking vascular-disrupting agents for self-amplified tumor-targeting therapy.

Chu H, Xu Y, Shan Y, Sun M, Zhao W, Fang X J Nanobiotechnology. 2025; 23(1):197.

PMID: 40059143 PMC: 11892306. DOI: 10.1186/s12951-025-03262-9.

Vascularised organoids: Recent advances and applications in cancer research.

Zhou R, Brislinger D, Fuchs J, Lyons A, Langthaler S, Hauser C Clin Transl Med. 2025; 15(3):e70258.

PMID: 40045486 PMC: 11882480. DOI: 10.1002/ctm2.70258.

Evaluating dynamic contrast-enhanced MRI for differentiating HER2-zero, HER2-low, and HER2-positive breast cancers in patients undergoing neoadjuvant chemotherapy.

Hu Y, Li M, Hu Y, Wang M, Lin Y, Mao L Eur J Med Res. 2025; 30(1):132.

PMID: 40001120 PMC: 11852569. DOI: 10.1186/s40001-024-02188-6.

Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies.

Arandhara A, Bhuyan P, Das B Discov Oncol. 2025; 16(1):159.

PMID: 39934547 PMC: 11814423. DOI: 10.1007/s12672-025-01902-y.

References

Jameson M, Thompson P, Baguley B, Evans B, Harvey V, Porter D . Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer. 2003; 88(12):1844-50. PMC: 2741109. DOI: 10.1038/sj.bjc.6600992. View

Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M . Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer. 2007; 97(7):888-94. PMC: 2360417. DOI: 10.1038/sj.bjc.6603969. View

Wilson W, Li A, Cowan D, Siim B . Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys. 1998; 42(4):905-8. DOI: 10.1016/s0360-3016(98)00358-7. View

Murata R, Overgaard J, Horsman M . Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol. 2001; 77(2):195-204. DOI: 10.1080/09553000010007695. View

Padera T, Kadambi A, Tomaso E, Carreira C, Brown E, Boucher Y . Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002; 296(5574):1883-6. DOI: 10.1126/science.1071420. View

Dickson P, Hamner J, Sims T, Fraga C, Ng C, Rajasekeran S . Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007; 13(13):3942-50. DOI: 10.1158/1078-0432.CCR-07-0278. View

Leu A, Berk D, Lymboussaki A, Alitalo K, Jain R . Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000; 60(16):4324-7. View

Grosios K, Loadman P, Swaine D, Pettit G, Bibby M . Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 2000; 20(1A):229-33. View

Hua J, Sheng Y, Pinney K, Garner C, Kane R, Prezioso J . Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 2003; 23(2B):1433-40. View

10.

Siemann D, Shi W . Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008; 28(4B):2027-31. PMC: 2788501. View

11.

Zwi L, Baguley B, Gavin J, Wilson W . Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res. 1994; 6(2):79-85. View

12.

Horti J, Juhasz E, Monostori Z, Maeda K, Eckhardt S, Bodrogi I . Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2008; 62(1):173-80. DOI: 10.1007/s00280-007-0665-7. View

13.

McKeage M, Reck M, Jameson M, Rosenthal M, Gibbs D, Mainwaring P . Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer. 2009; 65(2):192-7. DOI: 10.1016/j.lungcan.2009.03.027. View

14.

Wang L, Thomsen L, Sutherland R, Reddy C, Tijono S, Chen C . Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia. 2009; 11(8):793-803. PMC: 2713591. DOI: 10.1593/neo.09506. View

15.

Ma W, Hidalgo M . Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol. 2007; 13(44):5845-56. PMC: 4205431. DOI: 10.3748/wjg.v13.i44.5845. View

16.

Hori K, Saito S . Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer. 2003; 89(7):1334-44. PMC: 2394288. DOI: 10.1038/sj.bjc.6601261. View

17.

Cliffe S, Taylor M, Rutland M, Baguley B, Hill R, Wilson W . Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys. 1994; 29(2):373-7. DOI: 10.1016/0360-3016(94)90292-5. View

18.

Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, McDonald D . Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res. 2004; 94(7):984-92. DOI: 10.1161/01.RES.0000125295.43813.1F. View

19.

Korn E, Arbuck S, Pluda J, Simon R, Kaplan R, Christian M . Clinical trial designs for cytostatic agents: are new approaches needed?. J Clin Oncol. 2001; 19(1):265-72. DOI: 10.1200/JCO.2001.19.1.265. View

20.

Zhao L, Ching L, Kestell P, Baguley B . The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer. 2002; 87(4):465-70. PMC: 2376130. DOI: 10.1038/sj.bjc.6600479. View